Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

By R. Marcus, K. Imrie, P. Solal-Céligny, J. Catalano, A. Dmoszyńska, J. Raposo, F. Offner, J. Gomez-Codina, A. Belch, D. Cunningham and 2 more. Journal of Clinical Oncology, 2008

604 citations recorded by the source corpus.

Subfields: Dermatology, Neurology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/2dfcc33d346f1670986b310fd0dd867df2f90d13

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Maurer
2. John Hainsworth
3. Xiaolei Zhou
4. C. Flowers
5. James R. Cerhan
6. J. Friedberg
7. C. Farber
8. K. Dawson

Citations in the corpus

• Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. (2015, background): “The observation that 20% of patients with FL relapse within 2 years of treatment has been made in many studies of several chemoimmunotherapy regimens and is not altered with the addition of maintenance rituximab.(6-8,10-12,25) Validated tools for risk assessment and prognostication in newly diagnose”